HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

54.150

-2.950-5.17%

Volume:2.70M

Turnover:145.87M

Market Cap:10.78B

PE:-38.27

High:57.500

Open:56.950

Low:52.750

Close:57.100

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:1.25

T/O Rate:1.36%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.415

ROE:-51.55%

ROA:-12.87%

PB:9.90

PE(LYR):-38.27

PS:43.22

Loading ...

Overview Company News Filings

LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase

Leads Biolabs Advances PD-L1/4-1BB Bispecific Antibody LBL-024 into Expansion Phase of Phase II First-Line ESCC Trial

Bulletin Express

Leads Biolabs' Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Nda Accepted by Nmpa, Poised to Become World's First Approved 4-1Bb-Targeting Therapy

THOMSON REUTERS

Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody

Nanjing Leads Biolabs Says NMPA Accepts NDA for LBL-024 in Advanced EP-NEC

Nanjing Leads Biolabs Co - Nmpa Accepts Nda for Lbl-024 (Opamtistomig) for Advanced Ep-Nec

THOMSON REUTERS

Movement Alert｜LEADS BIOLABS-B Falls 5.65% in Regular Trading, Trading at HK$71.95

Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published

LEADS BIOLABS-B (09887) Triggers Option Exercise to Secure LBL-051 License

Nanjing Leads Biolabs Says Oblenio Exercises LBL-051 License Option, Triggering USD 10 Million Fee

Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation

Bulletin Express

Nanjing Leads Biolabs Schedules Board Meeting to Review Interim Results, Dividend Recommendation

Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum

Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment

Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

THOMSON REUTERS

Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase

Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage

Bulletin Express

LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/09887/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":54.15,"timestamp":1789542857055,"preClose":57.1,"halted":0,"volume":2701500,"delay":0,"changeRate":-0.05166374781085819,"floatShares":198000000,"shares":199000000,"eps":-1.4148225281405657,"marketStatus":"Trading","change":-2.95,"latestTime":"09-16 15:14:30","open":56.95,"high":57.5,"low":52.75,"amount":145868520,"amplitude":0.083187,"askPrice":54.15,"askSize":1300,"bidPrice":53.95,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-1.6101522248107623,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789546200000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":57.1,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":1.247622,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.414823,"volumeRatio":1.247622,"shares":199000000,"dividePrice":0,"high":57.5,"amplitude":0.083187,"preClose":57.1,"low":52.75,"week52Low":44.72,"pbRate":"9.90","psRate":"43.22","week52High":97.5,"institutionHeld":0,"latestPrice":54.15,"committee":0.212121,"eps":-1.4148225281405657,"divideRate":0,"volume":2701500,"delay":0,"ttmEps":-1.6101522248107623,"open":56.95,"prevYearClose":51,"prevWeekClose":60.2,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":63.2,"twentyDayClose":70.45,"sixtyDayClose":50.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-15","current":-33.630361,"percent":0.760714,"low":-76.458084,"twenty":-45.563334,"median":-39.87359,"eighty":-34.764068,"high":-30.202688,"avg":-42.038751,"sd":9.653343,"marketCap":11141443360},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-11","current":-37.6607,"twenty":-45.564242,"median":-39.940552,"eighty":-34.761336,"marketCap":11746320320},{"date":"2026-09-15","current":-35.727174,"twenty":-45.563334,"median":-39.87359,"eighty":-34.764068,"marketCap":11141443360}],"updateTime":1789542870053},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121426329","title":"LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1121426329","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121426329?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:00","pubTimestamp":1787612419,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the Phase II clinical study of its self-developed investigational drug Vilitrin (Opasotiumumab, a PD-L1/4-1BB bispecific antibody, LBL-024) for the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK4023","LU1169590202.USD","HK0000252160.HKD","LU1169589451.USD","PD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174574289","title":"Leads Biolabs Advances PD-L1/4-1BB Bispecific Antibody LBL-024 into Expansion Phase of Phase II First-Line ESCC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1174574289","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174574289?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:46","pubTimestamp":1787611599,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed bispecific antibody LBL-024 (Opamtistomig) has completed the safety lead-in portion of a Phase II study in first-line...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326621","title":"Leads Biolabs' Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Nda Accepted by Nmpa, Poised to Become World's First Approved 4-1Bb-Targeting Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661326621?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:21","pubTimestamp":1787304089,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148838562","title":"Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1148838562","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148838562?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:50","pubTimestamp":1787302229,"startTime":"0","endTime":"0","summary":"Leads Biolabs-B (09887) has announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has formally accepted the company's independently developed...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","LU1169590202.USD","BK4023","HK0000252160.HKD","IPOS","BK1161","PD","HK0000252152.HKD","09887","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661655402","title":"Nanjing Leads Biolabs Says NMPA Accepts NDA for LBL-024 in Advanced EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661655402","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661655402?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:42","pubTimestamp":1787301756,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NECNanjing Leads Biolabs’ NMPA drug review center accepted an NDA for LBL-024 (Opatlisumab), a PD-L1/4-1BB bispecific, in EP-NEC.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLc4nHQt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252160.HKD","BK1161","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265547","title":"Nanjing Leads Biolabs Co - Nmpa Accepts Nda for Lbl-024 (Opamtistomig) for Advanced Ep-Nec","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661265547?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:42","pubTimestamp":1787301730,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160907287","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.65% in Regular Trading, Trading at HK$71.95","url":"https://stock-news.laohu8.com/highlight/detail?id=1160907287","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160907287?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:43","pubTimestamp":1787276590,"startTime":"0","endTime":"0","summary":"On August 21, LEADS BIOLABS-B fell 5.65% in regular trading, trading at HK$71.95/share, with turnover of HK$29.23 million.Within the Biotechnology sector where LEADS BIOLABS-B belongs, the sector...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143205687","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.25% in Regular Trading, Oblenio Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","url":"https://stock-news.laohu8.com/highlight/detail?id=1143205687","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143205687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:58","pubTimestamp":1787194735,"startTime":"0","endTime":"0","summary":"On August 20, LEADS BIOLABS-B rose 5.25% in regular trading, trading at HK$74.5/share, with turnover of HK$83.28 million. The stock was lifted by a dual catalyst of a licensing milestone and clinical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Exercises LBL-051 Global License Option as WCLC Lung Cancer Data Published","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198582483","title":"LEADS BIOLABS-B (09887) Triggers Option Exercise to Secure LBL-051 License","url":"https://stock-news.laohu8.com/highlight/detail?id=1198582483","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198582483?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:44","pubTimestamp":1787179452,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that Oblenio Bio, Inc. (NewCo) has officially exercised its option to retain the exclusive license for LBL-051, marking a significant step forward in their...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660769234","title":"Nanjing Leads Biolabs Says Oblenio Exercises LBL-051 License Option, Triggering USD 10 Million Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2660769234","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660769234?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:16","pubTimestamp":1787177768,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Oblenio exercises LBL-051 license option, triggering USD 10 million feeOblenio exercised its option to retain the worldwide license for LBL-051, triggering a one-time US$ 10","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL3gmbQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161859865","title":"Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation","url":"https://stock-news.laohu8.com/highlight/detail?id=1161859865","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161859865?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:28","pubTimestamp":1787135308,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes: 1. Reviewing and approving the interim financial results of Leads...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660384444","title":"Nanjing Leads Biolabs Schedules Board Meeting to Review Interim Results, Dividend Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660384444","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660384444?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:11","pubTimestamp":1787134271,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs schedules board meeting to review interim results, dividend recommendationNanjing Leads Biolabs will hold a board meeting on Aug. 31, 2026.Directors are set to review interim res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL9sLqRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114260368","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.18% in Regular Trading, Dense Pipeline Catalysts Continue to Drive Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1114260368","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114260368?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:55","pubTimestamp":1786931757,"startTime":"0","endTime":"0","summary":"On August 17, LEADS BIOLABS-B rose 5.18% in regular trading, trading at HK$76.95/share, with turnover of HK$64.37 million.The rise extends recent momentum fueled by a series of clinical milestones....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises as Dense Pipeline Catalysts Continue to Drive Momentum","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145060311","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1145060311","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145060311?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:24","pubTimestamp":1786688645,"startTime":"0","endTime":"0","summary":"On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.The movement was driven by a cluster of recent positive developments. On August...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Rises, Multiple Pipeline Catalysts Drive Positive Sentiment","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657509468","title":"Nanjing Leads Biolabs Jumps on Progress of Tumor Antibody Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657509468","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657509468?lang=en_us&edition=fundamental","pubTime":"2026-08-06 12:57","pubTimestamp":1785992261,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads Biolabs jumps on progress of tumor antibody treatment** Shares of Nanjing Leads Biolabs9887.HKjump 8.3% to HK$62.85, the highest level since July 24** Stock of the China-based oncology therapies developer set for the biggest one-day pct gain since July 15** Company says Phase II clinical study evaluating its bispecific antibody PD-L1/4-1BB and Opamtistomig  for treatment of first-line hepatocellular carcinoma , or malignant tumor, has completed safety run in phase assessment review and has successfully entered expansion phase** Preliminary data show that Opamtistomig in combination with bevacizumab has demonstrated encouraging efficacy signals in patients with HCC with a favorable overall safety profile and good tolerability - co** YTD, stock up 23.1%, Hang Seng Biotech Index.HSBIOup 1.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N443044:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161568880","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1161568880","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161568880?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:55","pubTimestamp":1785984951,"startTime":"0","endTime":"0","summary":"On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657604570","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2657604570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657604570?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:53","pubTimestamp":1785977613,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUABKLW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572869","title":"Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572869?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:00","pubTimestamp":1785970810,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Phase II Opamtistomig trial in first-line liver cancer enters expansion phaseNanjing Leads Biolabs reported its Phase II study of LBL-024 (opamtistomig) for first-line hepat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4Rzf09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131250364","title":"Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131250364","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131250364?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:25","pubTimestamp":1785968734,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has completed the safety run-in of a Phase II study in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193898777","title":"LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1193898777","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193898777?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:20","pubTimestamp":1785968415,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that its independently developed PD-L1/4-1BB bispecific antibody, Opatsosumimab (Vilitis™), has successfully completed the safety run-in assessment in a Phase II...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":138,"code":"91000000","status":"200"}]}}